{"nctId":"NCT00401973","briefTitle":"Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine","startDateStruct":{"date":"2006-11"},"conditions":["Schizophrenia","Schizoaffective Disorders"],"count":199,"armGroups":[{"label":"Olanzapine","type":"EXPERIMENTAL","interventionNames":["Drug: olanzapine","Behavioral: Wellness education"]},{"label":"Olanzapine + Amantadine","type":"EXPERIMENTAL","interventionNames":["Drug: olanzapine","Drug: amantadine","Drug: metformin","Drug: zonisamide","Behavioral: Wellness education"]},{"label":"Olanzapine + Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: olanzapine","Drug: amantadine","Drug: metformin","Drug: zonisamide","Behavioral: Wellness education"]}],"interventions":[{"name":"olanzapine","otherNames":["LY170053","Zyprexa"]},{"name":"amantadine","otherNames":[]},{"name":"metformin","otherNames":[]},{"name":"zonisamide","otherNames":[]},{"name":"Wellness education","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* You must have been diagnosed with schizophrenia or schizoaffective disorder\n* You must be able to visit the doctor's office once every two weeks for three months, then once every four weeks for the next three months with a possible bi-weekly visit during the fifth month\n* If you are currently taking a medication for schizophrenia or schizoaffective disorder, you have been taking it for at least 30 days without any changes\n* If you are a female, you must have a negative pregnancy test and be using an effective method of contraception\n\nExclusion Criteria:\n\n* You have a diagnosis of bipolar I disorder, diabetes, very high triglyceride level (fasting triglycerides greater than or equal to 500 mg/dL), recent heart attack, stroke, uncontrolled seizures, serious infection, unstable heart disease (such as ischemic heart disease or congestive heart failure), an uncorrected narrow angle glaucoma or human immunodeficiency virus (HIV)\n* You have diseases of the intestinal tract, lungs, liver, kidney, nervous or endocrine systems, or blood\n* You have a diagnosis of an eating disorder\n* You have a history of Parkinson's Disease or any related disorders\n* You are allergic to sulfa drugs or any of the medications involved in this study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Endpoint in Weight","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.76","spread":"0.75"},{"groupId":"OG001","value":"2.40","spread":"0.65"},{"groupId":"OG002","value":"0.65","spread":"0.63"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint in Fasting Triglycerides","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":"0.81"},{"groupId":"OG001","value":"1.61","spread":"0.76"},{"groupId":"OG002","value":"1.68","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"1.01"},{"groupId":"OG001","value":"0.35","spread":"0.88"},{"groupId":"OG002","value":"0.06","spread":"0.64"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint in Fasting Total Cholesterol","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.01","spread":"1.00"},{"groupId":"OG001","value":"5.03","spread":"1.09"},{"groupId":"OG002","value":"4.91","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.84"},{"groupId":"OG001","value":"0.01","spread":"1.06"},{"groupId":"OG002","value":"-0.08","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.29"},{"groupId":"OG001","value":"1.26","spread":"0.36"},{"groupId":"OG002","value":"1.22","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.23"},{"groupId":"OG001","value":"-0.11","spread":"0.25"},{"groupId":"OG002","value":"-0.08","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":"0.88"},{"groupId":"OG001","value":"3.06","spread":"1.03"},{"groupId":"OG002","value":"2.91","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.60"},{"groupId":"OG001","value":"-0.04","spread":"0.95"},{"groupId":"OG002","value":"-0.02","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint in Fasting Glucose","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.32","spread":"0.46"},{"groupId":"OG001","value":"5.25","spread":"0.78"},{"groupId":"OG002","value":"5.28","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"0.99"},{"groupId":"OG001","value":"0.10","spread":"0.48"},{"groupId":"OG002","value":"0.01","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint in Hemoglobin A1c","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.51","spread":"0.46"},{"groupId":"OG001","value":"5.48","spread":"0.39"},{"groupId":"OG002","value":"5.53","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.45"},{"groupId":"OG001","value":"0.10","spread":"0.37"},{"groupId":"OG002","value":"-0.03","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score","description":"The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.24","spread":"15.98"},{"groupId":"OG001","value":"45.90","spread":"12.44"},{"groupId":"OG002","value":"47.00","spread":"14.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.89","spread":"18.61"},{"groupId":"OG001","value":"-9.90","spread":"11.24"},{"groupId":"OG002","value":"-9.72","spread":"14.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","description":"The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.76","spread":"8.08"},{"groupId":"OG001","value":"14.22","spread":"11.14"},{"groupId":"OG002","value":"15.40","spread":"9.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.39","spread":"8.37"},{"groupId":"OG001","value":"-4.12","spread":"7.20"},{"groupId":"OG002","value":"-4.36","spread":"7.47"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)","description":"Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.06","spread":"1.24"},{"groupId":"OG001","value":"4.03","spread":"1.07"},{"groupId":"OG002","value":"4.00","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":"1.13"},{"groupId":"OG001","value":"-0.72","spread":"1.14"},{"groupId":"OG002","value":"-0.79","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks","description":"To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.034","spread":null},{"groupId":"OG001","value":"0.285","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.273","spread":null},{"groupId":"OG001","value":"-0.038","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.150","spread":null},{"groupId":"OG001","value":"0.148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.013","spread":null},{"groupId":"OG001","value":"-0.064","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.019","spread":null},{"groupId":"OG001","value":"0.047","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.051","spread":null},{"groupId":"OG001","value":"0.043","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.022","spread":null},{"groupId":"OG001","value":"-0.008","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.039","spread":null},{"groupId":"OG001","value":"-0.000","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5},"commonTop":["Somnolence","Diarrhoea","Nausea","Weight increased","Insomnia"]}}}